Teva presents new data on Ajovy in chronic and episodic migraine

Israel’s largest drugmaker Teva Pharmaceutical Industries (NYSE: TEVA) has announced further positive data from the pan-European PEARL study investigating the impact of Ajovy (fremanezumab) on the prevention of migraine in a real-world setting, due to be completed in 2024.

The data from the third interim analysis reveals that almost 60% of patients achieved a ≥50% reduction in monthly migraine days from baseline for migraine prevention, with sustained improvement in disability scores and acute medication use observed over 12 months. Treatment persistence rates were high, with 82.3% of patients remaining on treatment by month 12.

Teva noted that not only was fremanezumab effective in preventing migraine attacks in patients with chronic and episodic migraine, it has also shown to be effective in reducing the severity and duration of remaining migraine attacks.